<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Brunner, Hermine I.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tocilizumab Significantly Reduces Flares in Polyarticular Juvenile Idiopathic Arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment with tocilizumab, a humanized monoclonal antibody that interrupts interleukin-6-mediated signaling, results in meaningful improvement of polyarticular-course juvenile idiopathic arthritis following methotrexate failure, with treatment responses maintained to at least 40 weeks. This article discusses findings from the A Study of Tocilizumab in Patients with Active Polyarticular-Course Juvenile Idiopathic Arthritis [CHERISH; NCT00988221] trial.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>